Scientia Clinical Research Limited

Randwick, New South Wales 2031

1 studies enrolling now · 4 studies all time

What they study most

Advanced Lymphoma, Advanced Solid Tumor, Colorectal Cancer, HER2-Positive Advanced Solid Tumor, HER2-Positive Salivary Gland Carcinomas, HER2-positive Biliary Tract Cancer, HER2-positive Breast Cancer, Multiple Myeloma, Non-small Cell Lung Cancer (NSCLC), Squamous Cell Cancer of Head and Neck (SCCHN)

Studies at this site

• A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas — Recruiting now
• A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer — Stopped early
• Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors — Status unconfirmed
• Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma — Completed